bluebird bio (NASDAQ:BLUE) Given New $8.00 Price Target at Barclays

bluebird bio (NASDAQ:BLUE) had its target price decreased by Barclays from $40.00 to $8.00 in a research note issued to investors on Monday,Benzinga reports. Barclays currently has an overweight rating on the biotechnology company’s stock.

A number of other research firms also recently commented on BLUE. StockNews.com started coverage on shares of bluebird bio in a research report on Friday. They set a “sell” rating on the stock. JPMorgan Chase & Co. upgraded bluebird bio from an “underweight” rating to a “neutral” rating in a research report on Monday, February 24th. Wells Fargo & Company lowered their price target on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Monday, February 24th. Finally, Baird R W lowered bluebird bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $44.60.

bluebird bio Price Performance

Shares of BLUE opened at $4.88 on Monday. bluebird bio has a one year low of $3.56 and a one year high of $28.60. The stock’s fifty day moving average is $5.46 and its 200-day moving average is $7.68. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.33 and a current ratio of 0.51. The firm has a market capitalization of $47.44 million, a price-to-earnings ratio of -0.13 and a beta of 0.76.

Hedge Funds Weigh In On bluebird bio

Several institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC raised its holdings in shares of bluebird bio by 8.1% during the third quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock worth $1,289,000 after acquiring an additional 186,903 shares in the last quarter. BNP Paribas Financial Markets increased its position in bluebird bio by 2,270.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 355,562 shares during the last quarter. Captrust Financial Advisors raised its stake in shares of bluebird bio by 48.2% during the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 77,293 shares in the last quarter. Verition Fund Management LLC bought a new position in bluebird bio during the third quarter valued at approximately $42,000. Finally, State Street Corp raised its holdings in shares of bluebird bio by 1.1% during the 3rd quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after purchasing an additional 43,382 shares in the last quarter. 87.43% of the stock is currently owned by hedge funds and other institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.